Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Thyroid Neoplasms 1Skin Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Lung Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 2Interleukin-2 2Biopsy 2montanide ISA 51 1liposomal doxorubicin 1cemiplimab 1cc-486 1brodalumab 1atezolizumab 1SUB1 protein, human 1Radiotherapy, Image-Guided 1Quality of Life 1Psychiatric Rehabilitation 1Poly I-C 1Patient Reported Outcome Measures 1Observation 1Molecular Diagnostic Techniques 1Mass Screening 1Injections 1Immunotherapy 1Immunohistochemistry 1IT-101 1Genetic Profile 1Floderm topical cream 1Drug Therapy 1Camptothecin 1CALAA-01 1Biological Therapy 1Azacitidine 12-cyclohexylidenhydrazo-4-phenyl-thiazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Skin Neoplasms × Camptothecin × Breast × Clear all
NCT00333502 2020-05-28

Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors

Lumos Pharma

Phase 1/2 Completed
62 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Skin Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡